Experience of entecavir therapy in chronic hepatitis B
https://doi.org/10.22625/2072-6732-2009-1-4-72-75
Abstract
Entecavir is a potent and selective guanosine analogue that has demonstrated a significant antiviral efficacy against hepatitis B virus. The purpose of this article was to characterize the response to entecavir and it portability. METHODS: We administered 0.5 mg of entecavir once daily for 52 weeks to 20 naive chronic hepatitis B patients. We measured the levels of liver enzymes, serological markers, and serum HBV DNA at 12-weeks, 24-weeks and 52-weeks. RESULTS: Normalization of serum alanine aminotransferase levels (normal range: woman <31 IU/mL , men <40 IU/mL) was observed in 90% (18/20), 85% (17/20), and 85% (17/20) of patients after 12, 24 and 52 weeks of therapy. HBV DNA levels of <300 copies/mL (as evaluated by polymerase chain reaction) were observed in 95%, 95% and 95% of patients after 12, 24 and 52 weeks. Viral breakthrough was not observed. CONCLUSIONS: Entecavir induced excellent biochemical and virologic responses in chronic hepatitis B patients.
About the Authors
E. V. Esaulenko
Research Institute of Influenza Northwestern Branch Russian Academy of Medical Sciences, Saint-Petersburg
Russian Federation
Russian Federation
J. S. Alikjan
Research Institute of Influenza Northwestern Branch Russian Academy of Medical Sciences, Saint-Petersburg
Russian Federation
Russian Federation
O. Y. Emelyanjva
Research Institute of Influenza Northwestern Branch Russian Academy of Medical Sciences, Saint-Petersburg
Russian Federation
Russian Federation
T. A. Stasishkis
Centre of prevention and struggle with AIDS
and infectious diseases, Leningrad Region
Russian Federation
Russian Federation
A. Y. Kovelenov
Centre of prevention and struggle with AIDS
and infectious diseases, Leningrad Region
Russian Federation
Russian Federation
References
1. Елпаева Е.А. Генотипическая характеристика вируса гепатита В у хронически инфицированных больных /Е.А. Елпаева // Дальневосточный журн. инфекционной патологии, 2009 – № 15. – с.56–59.
2. Arbuthnot P. Hepatitis B virus and hepatocellular carcinoma / P. Arbuthnot, M. Kew. // Int. J. Exp. Pathol., 2001. – № 82. – p.77–100.
3. Custer B. Global epidemiology of hepatitis B virus /B. Guster, S.D. Sullivan, T.K. Hazlet // Clin. Gastroenterrol., 2004. – № 38 (10 suppl). – p. 158–168.
4. Lai C.L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B / C.L. Lai // Engl. J. Med., 2006. – №354(10). – p.1011–1020.
5. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. / D. Lavanchy // J. Virol. Hepat., 2004. – № 11. – p. 97–107.
6. Locarnini S.A., Newbold J.E. Chronic hepatitis В the therapeutic challenge / S.A. Locarnini, J.E. Newbold // J. of Antimicrobial Chemotherapy, 1997. – № 39. – p. 559–565.
7. Lok A.S., McMachon B.J. Chronic hepatitis B /A.S. Lok, B.J. McMachon // J. Hepatol., 2001. – № 34. –p.1225–1241.
8. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000—summary of a workshop / A.S. Lok, E.J. Heathcote, J.H. Hoofnagle // J. Gastroenterol., – № 120. – 1828–1853.
9. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. Viral Hepat. 2009 Mar;16(3):149–55.
10. Piccolo P. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B / Piccolo P. [et al.] // J. Antivir Ther, 2009. – №14(8). – p.1165–74.
11. Cornberg M., Manns M.P. Entecavir-options and obstacles of an effective treatment for chronic hepatitis B. /M. Cornberg, M.P. Manns // J. Dtsch. Med. Wochenschr., 2010. – №135. –p. 32–37.
12. Pramoolsinsup C. Management of viral hepatitis B. J. Gastroenterol. Hepatol., 2002. – p.125–145.
Review
For citations:
Esaulenko E.V., Alikjan J.S., Emelyanjva O.Y., Stasishkis T.A., Kovelenov A.Y. Experience of entecavir therapy in chronic hepatitis B. Journal Infectology. 2009;1(4):72-75. (In Russ.) https://doi.org/10.22625/2072-6732-2009-1-4-72-75
Views:
630
.png)
.png)
Email this article 